A large global phase III randomized trial included breast cancer patients with 1-3 positive axillary lymph nodes and a Ki67 index > 20% treated with adjuvant endocrine therapy and abemaciclib, a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor. Here, MKI67 is linked to breast carcinoma.